A new type of coronavirus vaccine created by researchers from the University of Oxford has successfully passed the first phase of clinical trials, demonstrating signs of effectiveness and safety.
This is stated in an article published in the British medical journal The Lancet by the authors of the development.
вЂњWe have received encouraging results indicating the safety of the drug,вЂќ the article says.
вЂњNo serious side effects were detected. Seroconversion (the process by which the body produces antibodies) was observed in more than 96% of the study participants, and neutralizing antibodies were produced in 85% of them. 90% of participants also had a T-cell response, вЂњ the study authors note.
Earlier it was reported that a potential vaccine by scientists from the University of Oxford has already been put into production at seven enterprises in the UK, continental Europe, India, and China. It is expected that by September when clinical trials of the vaccine should be completed, about a million doses are planned to be manufactured.